Robert Kamen, Ph.D.
Bob Kamen joined Third Rock Ventures in 2010 to focus on the formation and development of biologics companies that develop life-changing therapies for patients. Bob brings more than 30 years of leadership experience in the pharmaceutical and biotechnology industries. Bob has played a key role in launching and building our portfolio companies:
- Former interim chief technology officer of Jounce Therapeutics
- Board member of Jounce Therapeutics
- Board member of Neon Therapeutics
Prior to Third Rock, Bob served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody product to achieve marketing approval and now the world’s top selling pharmaceutical. He was also a member of the Abbott Pharmaceuticals Executive Management Committee. Bob had been the president of BASF Bioresearch Corporation for ten years, until Abbott Laboratories acquired it in 2001. After retiring from Abbott, he was chairman and co-founder of BioAssets Development Corp., a biotherapeutics company focused on spinal diseases, which was acquired by Cephalon. Earlier in his career, he led discovery at the pioneering biotech company Genetics Institute Inc. He currently serves as a director of Harbour Antibodies BV, Lycera Corp. and Opsonic Therapeutics and advises other biopharmaceutical companies. Bob holds a B.S. in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University. During his academic scientific career he worked with DNA tumor viruses at Imperial Cancer Research Laboratories in London.
Bob spends his spare time pretending to be an athlete on his racing bike or walking with his best friend Chunk.